Exendin Peptide (9-39)

<strong>Exendin Peptide (9-39)</strong>_x000D_ <strong>Catalog number:</strong> B2012580_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 500 ug_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> Synthetic Peptide_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Collado Camps E, van Lith SAM, Kip A, Frielink C, Joosten L, Brock R, Gotthardt M. Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39) Eur J Nucl Med Mol Imaging. 2022 Nov 30._x000D_ 2: Leung K. 3-(4-Hydroxy-3-[(125)I]iodophenyl)propionate-exendin(9-39) 2010 Apr 6 [updated 2010 Jun 18]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013._x000D_ 3: Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update Diabetes Obes Metab. 2021 Sep;23 Suppl 3:5-29._x000D_ 4: Chopra A. (18)F-Labeled exendin(9-39) 2012 Feb 9 [updated 2012 May 17]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013._x000D_ 5: Gasbjerg LS, Bari EJ, Christensen M, Knop FK. Exendin(9-39)NH(2) : Recommendations for clinical use based on a systematic literature review Diabetes Obes Metab. 2021 Nov;23(11):2419-2436._x000D_ 6: Stefanovski D, Vajravelu ME, Givler S, De León DD. Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge Diabetes Care. 2022 Jun 2;45(6):1381-1390._x000D_ 7: Kimura H, Ogawa Y, Fujimoto H, Mukai E, Kawashima H, Arimitsu K, Toyoda K, Fujita N, Yagi Y, Hamamatsu K, Murakami T, Murakami A, Ono M, Nakamoto Y, Togashi K, Inagaki N, Saji H. Evaluation of (18)F-labeled exendin(9-39) derivatives targeting glucagon-like peptide-1 receptor for pancreatic β-cell imaging Bioorg Med Chem. 2018 Jan 15;26(2):463-469._x000D_ 8: Holst JJ, Gasbjerg LS, Rosenkilde MM. The Role of Incretins on Insulin Function and Glucose Homeostasis Endocrinology. 2021 Jul 1;162(7):bqab065._x000D_ 9: Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans J Clin Invest. 1998 Apr 1;101(7):1421-30._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/28953210">10: Ocampo-García BE, Santos-Cuevas CL, Luna-Gutiérrez MA, Ignacio-Alvarez E, Pedraza-López M, Manzano-Mayoral C. 99mTc-exendin(9-39)/octreotide: biokinetics and radiation dosimetry in healthy individuals Nucl Med Commun. 2017 Nov;38(11):912-918. </a>_x000D_ _x000D_ <strong>Products Related to Exendin Peptide (9-39) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>